Table 1 Characteristics of included studies and rating according to the Downs and Black checklist
Studies | Scoring | Classification | |||||||
|---|---|---|---|---|---|---|---|---|---|
Title | Author, year | Study design | Reporting | Ext. validity | Int. validity—bias | Int. validity—selection bias | Power | Total Score | Rating |
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis | Pinter (2022) [29] | Pooled analysis of two phase III clinical trials | 7 | 1 | 5 | 4 | 1 | 18 | Fair |
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study | Campanati (2021) [23] | Observational study | 10 | 3 | 6 | 2 | 1 | 22 | Good |
Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG | Jalili (2022) [22] | Post-hoc analysis | 8 | 3 | 7 | 4 | 1 | 23 | Good |
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial) | Lebwohl (2021) [43] | RCT | 10 | 3 | 7 | 5 | 1 | 26 | Excellent |
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use | Navarro-Triviño (2021) [38] | Observational study | 9 | 1 | 4 | 4 | 0 | 18 | Fair |
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream | Stein Gold (2021) [28] | RCT | 9 | 3 | 4 | 4 | 1 | 21 | Good |
Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body | Velasco (2019) [42] | Observational study | 6 | 1 | 2 | 2 | 0 | 11 | Poor |
Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions | Gerdes (2017) [30] | Observational study | 7 | 3 | 5 | 2 | 0 | 17 | Fair |
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study | Hong (2017) [25] | RCT | 9 | 3 | 5 | 5 | 1 | 23 | Good |
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study | Paul (2017) [26] | Subgroup analysis | 9 | 3 | 6 | 4 | 0 | 22 | Good |
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study | Paul (2017) [24] | RCT | 10 | 3 | 6 | 4 | 1 | 24 | Good |
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris–A randomized phase II study | Koo (2016) [27] | RCT | 10 | 3 | 6 | 5 | 0 | 24 | Good |
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study | Lambert (2015) [39] | Observational study | 6 | 1 | 4 | 0 | 0 | 11 | Poor |
Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet® Gel) and improvement of quality of life in patients with psoriasis | Sticherling (2013) [31] | Observational study | 10 | 2 | 4 | 3 | 0 | 19 | Fair |
Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1% | Korting (2012) [40] | RCT | 5 | 0 | 4 | 4 | 0 | 13 | Poor |
The DESIRE study–psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice | Claréus (2009) [32] | Observational study | 6 | 2 | 4 | 3 | 0 | 15 | Fair |
Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis | Lebwohl (2009) [20] | Clinical Trial | 6 | 3 | 4 | 3 | 0 | 16 | Fair |
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes | Koo (2006) [33] | RCT | 6 | 0 | 6 | 4 | 0 | 16 | Fair |
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris | Kragballe (2006) [21] | RCT | 10 | 3 | 6 | 6 | 1 | 26 | Excellent |
Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis | Lowe (2005) [34] | RCT | 7 | 0 | 4 | 4 | 1 | 16 | Fair |
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis | Decroix (2004) [35] | RCT | 7 | 0 | 6 | 3 | 0 | 16 | Fair |
Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis | Bergstrom (2003) [36] | RCT | 8 | 0 | 5 | 2 | 0 | 15 | Fair |
Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis | Sharma (2003) [37] | RCT | 9 | 0 | 5 | 1 | 0 | 15 | Fair |
Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice | Lambert (2002) [41] | Clinical Trial | 6 | 1 | 3 | 1 | 0 | 11 | Poor |